Cargando…

Abrogating Metastatic Properties of Triple-Negative Breast Cancer Cells by EGFR and PI3K Dual Inhibitors

SIMPLE SUMMARY: Triple-negative breast cancer (TNBC) is an aggressive BC that highly metastasizes to the brain, constituting a major hurdle and with poor survival after diagnosis. This strongly contributes to the lack of well-defined molecular targets, limiting effective TNBC therapeutic options. Ne...

Descripción completa

Detalles Bibliográficos
Autores principales:	Garcia, Ana Rita, Mendes, Avilson, Custódia, Carlos, Faria, Cláudia C., Barata, João T., Malhó, Rui, Figueira, Inês, Brito, Maria Alexandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10416979/ https://www.ncbi.nlm.nih.gov/pubmed/37568789 http://dx.doi.org/10.3390/cancers15153973

Ejemplares similares

MEF2C and miR-194-5p: New Players in Triple Negative Breast Cancer Tumorigenesis
por: Caetano, Sara, et al.
Publicado: (2023)

Behind Brain Metastases Formation: Cellular and Molecular Alterations and Blood–Brain Barrier Disruption
por: Godinho-Pereira, Joana, et al.
Publicado: (2021)

BSCI-04 TARGETING THE PI3K-MTOR PATHWAY TO TREAT UBE2C-DRIVEN BRAIN METASTASES
por: Paisana, Eunice, et al.
Publicado: (2022)

Targeting EGFR in Triple Negative Breast Cancer
por: Ueno, Naoto T., et al.
Publicado: (2011)

Targeting ANXA1 abrogates Treg-mediated immune suppression in triple-negative breast cancer
por: Bai, Fang, et al.
Publicado: (2020)

Halting Retrograde Transport Excludes ErbB-2 From the Nucleus Abrogating Tumor Growth in Triple Negative Breast Cancer
por: Madera, Santiago, et al.
Publicado: (2021)

LMD-12. Ubiquitin Conjugating Enzymes promote leptomeningeal dissemination and decrease survival in patients with brain metastatic disease
por: Paisana, Eunice, et al.
Publicado: (2021)

A Drug Screening Reveals Minocycline Hydrochloride as a Therapeutic Option to Prevent Breast Cancer Cells Extravasation across the Blood–Brain Barrier
por: Godinho-Pereira, Joana, et al.
Publicado: (2022)

Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
por: Secq, V, et al.
Publicado: (2014)

UBE2C promotes leptomeningeal dissemination and is a therapeutic target in brain metastatic disease
por: Paisana, Eunice, et al.
Publicado: (2023)

Differential Impact of EGFR-Targeted Therapies on Hypoxia Responses: Implications for Treatment Sensitivity in Triple-Negative Metastatic Breast Cancer
por: El Guerrab, Abderrahim, et al.
Publicado: (2011)

Inhibition of the PI3K/AKT pathway potentiates cytotoxicity of EGFR kinase inhibitors in triple-negative breast cancer cells
por: Yi, Yong Weon, et al.
Publicado: (2013)

PI3K inhibition circumvents resistance to SHP2 blockade in metastatic triple-negative breast cancer
por: Amante, Romain J., et al.
Publicado: (2023)

Sodium cantharidate targets STAT3 and abrogates EGFR inhibitor resistance in osteosarcoma
por: Ji, Xiang Lu, et al.
Publicado: (2019)

Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers
por: Linklater, Erik S., et al.
Publicado: (2016)

Expression and clinical significance of MAPK and EGFR in triple-negative breast cancer
por: Jiang, Weihua, et al.
Publicado: (2020)

Dual PI3K and Wnt pathway inhibition is a synergistic combination against triple negative breast cancer
por: Solzak, Jeffrey P., et al.
Publicado: (2017)

Dual inhibition of EGFR and MET induces synthetic lethality in triple-negative breast cancer cells through downregulation of ribosomal protein S6
por: YI, YONG WEON, et al.
Publicado: (2015)

Abrogation of the anti-metastatic activity of C. parvum by antilymphocyte serum.
por: Sadler, T. E., et al.
Publicado: (1976)

Patient-derived models of brain metastases recapitulate human disseminated disease
por: Faria, Claudia C., et al.
Publicado: (2022)

Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer
por: Guerrab, Abderrahim El, et al.
Publicado: (2016)

Nanobiopolymer for Direct Targeting and Inhibition of EGFR Expression in Triple Negative Breast Cancer
por: Inoue, Satoshi, et al.
Publicado: (2012)

Correlation of CK5 and EGFR with Clinicopathological Profile of Triple-Negative Breast Cancer
por: Sood, Neelam, et al.
Publicado: (2014)

Small Peptide Ligands for Targeting EGFR in Triple Negative Breast Cancer Cells
por: Hossein-Nejad-Ariani, Hanieh, et al.
Publicado: (2019)

Anti‐EGFR antibody‐drug conjugate for triple‐negative breast cancer therapy
por: Si, Yingnan, et al.
Publicado: (2020)

KLHL29-mediated DDX3X degradation promotes chemosensitivity by abrogating cell cycle checkpoint in triple-negative breast cancer
por: Yao, Litong, et al.
Publicado: (2023)

Dual Target of EGFR and mTOR Suppresses Triple-Negative Breast Cancer Cell Growth by Regulating the Phosphorylation of mTOR Downstream Proteins
por: Ma, Jing, et al.
Publicado: (2023)

Therapeutic Strategies for Metastatic Triple-Negative Breast Cancers: From Negative to Positive
por: Nandini, Dey, et al.
Publicado: (2021)

Triple-negative breast cancer and radiation therapy
por: de Faria Bessa, Jordana, et al.
Publicado: (2022)

Metastatic and triple-negative breast cancer: challenges and treatment options
por: Al-Mahmood, Sumayah, et al.
Publicado: (2018)

Patterns of Mutation Enrichment in Metastatic Triple-Negative Breast Cancer
por: Saravia, César H, et al.
Publicado: (2019)

How I treat metastatic triple-negative breast cancer
por: Caparica, Rafael, et al.
Publicado: (2019)

Overview of recent advances in metastatic triple negative breast cancer
por: O'Reilly, David, et al.
Publicado: (2021)

Emerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer
por: Cipriano, Élia, et al.
Publicado: (2021)

Checkpoint inhibitor therapy for metastatic triple-negative breast cancer
por: Heeke, Arielle L., et al.
Publicado: (2021)

Emerging treatment strategies for metastatic triple-negative breast cancer
por: Huppert, Laura A., et al.
Publicado: (2022)

Inhibition of GRP78 abrogates radioresistance in oropharyngeal carcinoma cells after EGFR inhibition by cetuximab
por: Sun, Chaonan, et al.
Publicado: (2017)

cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer
por: Sohn, Joohyuk, et al.
Publicado: (2014)

Novel Adamantanyl-Based Thiadiazolyl Pyrazoles Targeting EGFR in Triple-Negative Breast Cancer
por: Sebastian, Anusha, et al.
Publicado: (2016)

Surface roughness modulates EGFR signaling and stemness of triple-negative breast cancer cells
por: Rosado-Galindo, Heizel, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_u0vpgbed2ho9u7tvdt1cler29l